[go: up one dir, main page]

PE20080094A1 - COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO - Google Patents

COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO

Info

Publication number
PE20080094A1
PE20080094A1 PE2007000509A PE2007000509A PE20080094A1 PE 20080094 A1 PE20080094 A1 PE 20080094A1 PE 2007000509 A PE2007000509 A PE 2007000509A PE 2007000509 A PE2007000509 A PE 2007000509A PE 20080094 A1 PE20080094 A1 PE 20080094A1
Authority
PE
Peru
Prior art keywords
ethyl
methyl
compounds
agonist activity
hydroxyethylamine
Prior art date
Application number
PE2007000509A
Other languages
English (en)
Inventor
Pierre-Jean Colson
Adam D Hughes
Craig Husfeld
Mathai Mammen
Miroslaw Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of PE20080094A1 publication Critical patent/PE20080094A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

REFERIDA A UN DERIVADO DE DIALQUILFENILO DE FORMULA (I), DONDE R1 ES METILO O ETILO; R2 ES METILO O ETILO. SONCOMPUESTOS PREFERIDOS: ESTER 1-[2-(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-DIMETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO, ESTER 1-[2-(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-DIETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO, ESTER 1-[2-(4-{[(R)-2-(3-FORMILAMINO-4-HIDROXIFENIL)-2-HIDROXIETILAMINO]METIL}-2,5-ETILFENILCARBAMOIL)ETIL]PIPERIDIN-4-ILICO DEL ACIDO BIFENIL-2-ILCARBAMICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA UNA COMPOSICION FARMACEUTICA, UN PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR BETA 2 ADRENERGICO Y ANTAGONISTAS DEL RECEPTOR MUSCARINICO Y SON UTILES EN EL TRATAMIENTO DE AFECCIONES PULMONARES
PE2007000509A 2006-04-25 2007-04-24 COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO PE20080094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25

Publications (1)

Publication Number Publication Date
PE20080094A1 true PE20080094A1 (es) 2008-02-17

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000509A PE20080094A1 (es) 2006-04-25 2007-04-24 COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO

Country Status (20)

Country Link
US (3) US7524965B2 (es)
EP (1) EP2010489B1 (es)
JP (1) JP2009541209A (es)
KR (1) KR20090005389A (es)
CN (1) CN101426764A (es)
AR (1) AR060647A1 (es)
AU (1) AU2007243481A1 (es)
BR (1) BRPI0710767A2 (es)
CA (1) CA2650530A1 (es)
CO (1) CO6140054A2 (es)
ES (1) ES2391584T3 (es)
IL (1) IL194334A0 (es)
MA (1) MA30556B1 (es)
MX (1) MX2008013555A (es)
NO (1) NO20084603L (es)
PE (1) PE20080094A1 (es)
RU (1) RU2008146383A (es)
TW (1) TW200811105A (es)
WO (1) WO2007127196A2 (es)
ZA (1) ZA200808817B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
PT2242759E (pt) * 2008-02-06 2012-12-17 Astrazeneca Ab Compostos
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
EP2456868A4 (en) 2009-07-22 2013-11-06 Puretech Ventures METHOD AND COMPOSITIONS FOR TREATING SUFFERING OF SUFFERING THROUGH MUSCARIN RECEPTOR ACTIVATION
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
JP7096441B2 (ja) 2018-09-28 2022-07-05 カルナ セラピューティックス，インコーポレイテッド ムスカリン受容体活性化によって改善される障害を処置するための組成物及び方法
CN114409556B (zh) * 2022-01-28 2024-10-18 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
ES2296923T3 (es) * 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
WO2005087735A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
JP2009541209A (ja) 2009-11-26
EP2010489A2 (en) 2009-01-07
WO2007127196A3 (en) 2007-12-21
NO20084603L (no) 2008-11-19
ZA200808817B (en) 2010-03-31
US20070249675A1 (en) 2007-10-25
AR060647A1 (es) 2008-07-02
AU2007243481A1 (en) 2007-11-08
CN101426764A (zh) 2009-05-06
MA30556B1 (fr) 2009-07-01
US20090176833A1 (en) 2009-07-09
CO6140054A2 (es) 2010-03-19
WO2007127196A2 (en) 2007-11-08
ES2391584T3 (es) 2012-11-28
US7687521B2 (en) 2010-03-30
US20100137603A1 (en) 2010-06-03
IL194334A0 (en) 2009-08-03
RU2008146383A (ru) 2010-05-27
CA2650530A1 (en) 2007-11-08
EP2010489B1 (en) 2012-08-22
US7524965B2 (en) 2009-04-28
US8134006B2 (en) 2012-03-13
TW200811105A (en) 2008-03-01
BRPI0710767A2 (pt) 2011-06-07
MX2008013555A (es) 2008-11-04
KR20090005389A (ko) 2009-01-13

Similar Documents

Publication Publication Date Title
PE20080094A1 (es) COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO
NI200700161A (es) Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo
PE20120578A1 (es) Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
ATE459619T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
DE602005019043D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
ECSP088863A (es) Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
PE20091653A1 (es) Derivados sustituidos de pirazol y su uso
EP4537899A3 (en) Benzimidazole carboxylic acids as glp-1r agonists
SMT201300060B (it) Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico
PE20121433A1 (es) Compuestos de indazol y pirazolopiridina como antagonistas del receptor de ccr1
PE20120775A1 (es) Derivados de tienopirimidindiona como moduladores de trpa1
PE20071112A1 (es) Derivados azufrados de urea ciclica como inhibidores de quinasas y su preparacion
PE20090992A1 (es) Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
EA200900244A1 (ru) Модуляторы активности хемокиновых рецепторов, их кристаллические формы и способ их получения
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
ATE473961T1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
PE20091718A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas con actividad antiviral
PE20110331A1 (es) 7-sulfanilmetil-, 7-sulfinilmetil- y 7-sulfonilmetilindoles sustituidos y el uso de los mismos
PE20061195A1 (es) Derivado de bencimidazol como antagonista de angiotensina ii

Legal Events

Date Code Title Description
FC Refusal